Radiation Oncology Journal最新文献_第9页

Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer. 非小细胞肺癌10分次低分割放疗的安全性和有效性。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-09-01 Epub Date: 2021-09-09 DOI: 10.3857/roj.2021.00416

Ye Jin Yoo, Su Ssan Kim, Si Yeol Song, Jong Hoon Kim, Seung Do Ahn, Sang-Wook Lee, Sang Min Yoon, Young Seok Kim, Jin-Hong Park, Jinhong Jung, Eun Kyung Choi

{"title":"Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer.","authors":"Ye Jin Yoo, Su Ssan Kim, Si Yeol Song, Jong Hoon Kim, Seung Do Ahn, Sang-Wook Lee, Sang Min Yoon, Young Seok Kim, Jin-Hong Park, Jinhong Jung, Eun Kyung Choi","doi":"10.3857/roj.2021.00416","DOIUrl":"https://doi.org/10.3857/roj.2021.00416","url":null,"abstract":"Purpose: To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT) at our institution.Materials and methods: From May 2007 to December 2018, HFRT was used to treat 68 lesions in 64 patients who were unsuitable for SBRT because of central tumor location, large tumor size, or contiguity with the chest wall. The HFRT schedule included a dose of 50-70 Gy delivered in 10 fractions over 2 weeks. The primary outcome was freedom from local progression (FFLP), and the secondary endpoints included overall survival (OS), disease-free survival, and toxicities.Results: The median follow-up period was 25.5 months (range, 5.3 to 119.9 months). The FFLP rates were 79.8% and 67.8% at 1 and 2 years, respectively. The OS rates were 82.8% and 64.1% at 1 and 2 years, respectively. A larger planning target volume was associated with lower FFLP (p = 0.023). Dose escalation was not associated with FFLP (p = 0.964). Four patients (6.3%) experienced grade 3-5 pulmonary toxicities. Tumor location, central or peripheral, was not associated with either grade 3 or higher toxicity.Conclusion: HFRT with 50-70 Gy in 10 fractions demonstrated acceptable toxicity; however, the local control rate can be improved compared with the results of SBRT. More studies are required in patients who are unfit for SBRT to investigate the optimal fractionation scheme.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/17/roj-2021-00416.PMC8497873.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytogenetic biological dosimetry assays: recent developments and updates. 细胞遗传生物剂量测定:最近的发展和更新。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-09-01 Epub Date: 2021-06-24 DOI: 10.3857/roj.2021.00339

Tamizh Selvan Gnanasekaran

引用次数: 6

Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer. 前列腺根治术与外束放疗治疗高危前列腺癌的比较。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-09-01 Epub Date: 2021-09-09 DOI: 10.3857/roj.2021.00486

Seok-Joo Chun, Jin Ho Kim, Ja Hyeon Ku, Cheol Kwak, Eun Sik Lee, Suzy Kim

{"title":"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.","authors":"Seok-Joo Chun, Jin Ho Kim, Ja Hyeon Ku, Cheol Kwak, Eun Sik Lee, Suzy Kim","doi":"10.3857/roj.2021.00486","DOIUrl":"https://doi.org/10.3857/roj.2021.00486","url":null,"abstract":"Purpose: We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP).Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS).Results: Of 583 patients met the inclusion criteria (77 EBRT and 506 RP). The estimated 10-year PCSS was 97.0% in the RP and 95.9% in the EBRT (p = 0.770). No significant difference was seen in the DMFS (p = 0.540), whereas there was a trend in favor of RP over EBRT in overall survival (OS) (p = 0.068). Propensity score matching analysis with confounding variables was done, with 183 patients (66 EBRT and 117 RP) were included. No significant difference in DMFS, PCSS or OS was found.Conclusion: Our data demonstrated similar oncologic PCSS, OS, and DMFS outcomes between EBRT and RP patients.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/eb/roj-2021-00486.PMC8497867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39488920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review. 局部晚期直肠癌长期放化疗强化的当前方法综述。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-25 DOI: 10.3857/roj.2021.00108

Peiman Haddad, Reza Ghalehtaki, Arefeh Saeedian, Farshid Farhan, Mohammad Babaei, Mahdi Aghili

{"title":"Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review.","authors":"Peiman Haddad, Reza Ghalehtaki, Arefeh Saeedian, Farshid Farhan, Mohammad Babaei, Mahdi Aghili","doi":"10.3857/roj.2021.00108","DOIUrl":"https://doi.org/10.3857/roj.2021.00108","url":null,"abstract":"Rectal cancer is one of the most prevalent cancers in the world. In many countries, the current standard of care is long-course chemoradiation (CRT), followed by total mesorectal excision. Some efforts have been made by intensifying radiation or chemotherapy components of the neoadjuvant therapy to further decrease the local recurrence and augment surgery's feasibility and improve the oncological outcomes. This paper reviews recent intensified neoadjuvant interventions in locally advanced rectal cancer (LARC) in terms of efficacy and treatment-related toxicity. Many maneuvers have been made so far to improve the oncological outcomes of rectal cancer with intensified neoadjuvant long-course CRT. Some of these approaches seem compelling and deserve further study, while some have just increased the treatment-related toxicities without evident benefits. Those endeavors with greater pathological complete response than the standard of care may make us await the long-term results on survival rates and chronic treatment-related toxicity. After introduction of neoadjuvant CRT for LARC there have been many efforts to improve its outcomes. Here, this study gathered most of these efforts that intensified the neoadjuvant therapy with some being promising and some being futile.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/62/roj-2021-00108.PMC8497854.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39497061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Intrathyroidal parathyroid carcinoma: a case report and literature review. 甲状旁腺癌1例报告并文献复习。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-03-24 DOI: 10.3857/roj.2020.01060

Kenza Benali, Jihan Aarab, Houda Benmessaoud, Abdelati Nourreddine, Sanaa El Majjaoui, Hanan El Kacemi, Tayeb Kebdani, Noureddine Benjaafar

引用次数: 4

Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data. 隐匿性乳腺癌腋窝淋巴结转移患者的预后:多中心数据分析。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-15 DOI: 10.3857/roj.2021.00241

Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi

{"title":"Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data.","authors":"Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi","doi":"10.3857/roj.2021.00241","DOIUrl":"https://doi.org/10.3857/roj.2021.00241","url":null,"abstract":"Purpose: This study was conducted to evaluate prognosis of patients with level I/II axillary lymph node metastases from occult breast cancer (OBC).Materials and methods: Data of 53 patients with OBC who received axillary lymph node dissection (ALND) positive/negative (+/-) breast-conserving surgery between 2001 and 2013 were retrospectively collected at seven hospitals in Korea. The median number of positive lymph nodes (+LNs) was 2. Seventeen patients (32.1%) had >3 +LNs. A total of 48 patients (90.6%) received radiotherapy. Extents of radiotherapy were as follows: whole-breast (WB; n = 11), regional lymph node (RLN; n = 2), and WB plus RLN (n = 35).Results: The median follow-up time was 85 months. Recurrence was found in four patients: two in the breast, one in RLN, and one in the breast and RLN. The 5-year and 7-year disease-free survival (DFS) rates were 96.1% and 93.5%, respectively. Molecular subtype and receipt of breast radiotherapy were significantly associated with DFS. Patients with estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) subtype had significantly lower 7-year DFS than those with non-ER-/PR-/HER2- tumor (76.9% vs. 100.0%; p = 0.03). Whole breast irradiation (WBI) was significantly associated with a higher 7-year DFS rate (94.7% for WBI group vs. 83.3% for non-WBI group; p = 0.01). Other factors including patient's age, number of +LNs, taxane chemotherapy, and RLN irradiation were not associated with DFS.Conclusion: Patients with OBC achieved favorable outcome after ALND and breast-targeting treatment. Molecular subtype and receipt of WBI was significant factors for DFS.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/2a/roj-2021-00241.PMC8497863.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39494472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis. 90钇放射栓塞联合立体定向放射治疗门静脉肿瘤血栓形成。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-18 DOI: 10.3857/roj.2021.00213

Jason Liu, Colton Ladbury, Arya Amini, Scott Glaser, Jonathan Kessler, Aram Lee, Yi-Jen Chen

{"title":"Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis.","authors":"Jason Liu, Colton Ladbury, Arya Amini, Scott Glaser, Jonathan Kessler, Aram Lee, Yi-Jen Chen","doi":"10.3857/roj.2021.00213","DOIUrl":"10.3857/roj.2021.00213","url":null,"abstract":"Purpose: Portal vein tumor thrombosis (PVTT) from cancer involving the liver carries a dismal prognosis, with median overall survival (OS) ranging from 2 to 5 months. While treatment with yttrium-90 (90Y) radioembolization alone may improve outcomes, overall prognosis remains poor. We hypothesize that the combination of 90Y radioembolization to the parenchymal component of the tumor and stereotactic body radiation therapy (SBRT) to the vascular component is a safe and effective means of improving outcomes.Materials and methods: A single center retrospective review identified 12 patients with cancers involving the liver who received both 90Y radioembolization and SBRT to the PVTT between May 2015 to August 2020. Primary endpoint was the 90-day toxicity rate by the Common Terminology Criteria for Adverse Events version 5.0. Secondary endpoints were the best response rate based on the Response Evaluation Criteria in Solid Tumors v1.1, local control rate, portal vein (PV) patency rate, and median OS.Results: Patients received a median 90Y dose of 104.3 Gy (range, 83.3 to 131.7 Gy) and a median 5-fraction SBRT dose of 32.5 Gy (range, 27.5 to 50 Gy). There were no late toxicities reported, and only 7 acute grade 1 toxicities reported: elevation of liver function tests (17%), nausea (17%), fatigue (17%), and esophagitis (8%). Local control was 83%. 58% of patients had a patent PV after treatment. With a median follow-up time of 28 months, 1-year OS was 55% with a median OS of 14 months.Conclusion: Combination 90Y radioembolization and SBRT appears to be safe and effective in the treatment of PVTT. Larger prospective studies are warranted to better evaluate this combination treatment approach.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/ee/roj-2021-00213.PMC8497860.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39494473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy. 前列腺癌质子治疗中剂量-体积直方图参数和患者报告的epic -肠结构域。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-24 DOI: 10.3857/roj.2021.00388

Gabriella F Bulman, Ronik S Bhangoo, Todd A DeWees, Molly M Petersen, Cameron S Thorpe, William W Wong, Jean Claude M Rwigema, Thomas B Daniels, Sameer R Keole, Steven E Schild, Carlos E Vargas

{"title":"Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy.","authors":"Gabriella F Bulman, Ronik S Bhangoo, Todd A DeWees, Molly M Petersen, Cameron S Thorpe, William W Wong, Jean Claude M Rwigema, Thomas B Daniels, Sameer R Keole, Steven E Schild, Carlos E Vargas","doi":"10.3857/roj.2021.00388","DOIUrl":"https://doi.org/10.3857/roj.2021.00388","url":null,"abstract":"Purpose: To analyze rectal dose and changes in quality of life (QOL) measured with the Expanded Prostate and Cancer Index Composite (EPIC) bowel domain in patients being treated for prostate cancer with curative-intent proton beam therapy (PBT) within a large single-institution prospective registry.Materials and methods: Data was collected from 243 patients with localized prostate cancer treated with PBT from 2016 to 2018. The EPIC survey was administered at baseline, end-of-treatment, 3, 6, and 12 months, then annually. Dose-volume histogram (DVH) parameters for the rectum were computed, and rectal dose was analyzed using BED (α/β = 3), EQD2Gy, and total dose. Repeated measures mixed models were implemented to determine the effect of patient, clinical, and treatment factors (including DVH) on patient-reported bowel symptom burden (EPIC-Bowel).Results: Treatment overall resulted in changes in EPIC-Bowel scores (baseline score = 93.7), most notably at end-of-treatment (90.6) and 12 months (89.7). However, they returned to baseline at 36 months (92.9). On multivariate modeling, rectal BED D25 (Gy) ≥23% was significantly associated with decline in QOL scores measuring bother (p < 0.01; 4.06 points different).Conclusion: Rectal doses, specifically BED D25 (Gy) ≥23%, are significantly associated with decline in bowel bother-related QOL in patients undergoing definitive radiotherapy for localized prostate cancer. This study demonstrates BED as an independent predictor of bowel QOL across dose fractionations of PBT.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/fb/roj-2021-00388.PMC8497859.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39494474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Use of GammaPlan convolution algorithm for dose calculation on CT and cone-beam CT images. 使用GammaPlan卷积算法对CT和锥束CT图像进行剂量计算。

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-16 DOI: 10.3857/roj.2020.00640

Prabhakar Ramachandran, Ben Perrett, Orrie Dancewicz, Venkatakrishnan Seshadri, Catherine Jones, Akash Mehta, Matthew Foote

{"title":"Use of GammaPlan convolution algorithm for dose calculation on CT and cone-beam CT images.","authors":"Prabhakar Ramachandran, Ben Perrett, Orrie Dancewicz, Venkatakrishnan Seshadri, Catherine Jones, Akash Mehta, Matthew Foote","doi":"10.3857/roj.2020.00640","DOIUrl":"https://doi.org/10.3857/roj.2020.00640","url":null,"abstract":"Purpose: The aim of this study was to assess the suitability of using cone-beam computed tomography images (CBCTs) produced in a Leksell Gamma Knife (LGK) Icon system to generate electron density information for the convolution algorithm in Leksell GammaPlan (LGP) Treatment Planning System (TPS).Materials and methods: A retrospective set of 30 LGK treatment plans generated for patients with multiple metastases was selected in this study. Both CBCTs and fan-beam CTs were used to provide electron density data for the convolution algorithm. Plan quality metrics such as coverage, selectivity, gradient index, and beam-on time were used to assess the changes introduced by convolution using CBCT (convCBCT) and planning CT (convCT) data compared to the homogeneous TMR10 algorithm.Results: The mean beam-on time for TMR10 and convCBCT was found to be 18.9 ± 5.8 minutes and 21.7 ± 6.6 minutes, respectively. The absolute mean difference between TMR10 and convCBCT for coverage, selectivity, and gradient index were 0.001, 0.02, and 0.0002, respectively. The calculated beam-on times for convCBCT were higher than the time calculated for convCT treatment plans. This is attributed to the considerable variation in Hounsfield values (HU) dependent on the position within the field of view.Conclusion: The artifacts from the CBCT's limited field-of-view and considerable HU variation need to be taken into account before considering the use of convolution algorithm for dose calculation on CBCT image datasets, and electron data derived from the onboard CBCT should be used with caution.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/b7/roj-2020-00640.PMC8497862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39494475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Abscopal effect after palliative five-fraction radiation therapy on bone and lymph node metastases from luminal B breast cancer: a case report and clinical implications for palliative radiation therapy. 姑息性五分放射治疗对B腔乳腺癌骨和淋巴结转移的体外效应:1例报告及姑息性放射治疗的临床意义

IF 2.3

Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-04-16 DOI: 10.3857/roj.2020.00990

Tae Hyung Kim, Jee Suk Chang

引用次数: 6